Cagrilintide: an amylin analogue in metabolic research

Most of the attention in metabolic peptide research has gone to the incretins — GLP-1 and GIP. Cagrilintide comes from a different hormone family entirely: amylin. That distinct origin is why researchers study it alongside, rather than instead of, the GLP-1 analogues.

What amylin is

Amylin is a hormone co-secreted with insulin by the pancreas in response to food. In laboratory models it is studied for its role in satiety signalling and in slowing gastric emptying — effects that complement, rather than duplicate, those of the incretin hormones. Cagrilintide is a synthetic long-acting analogue of this hormone.

Why an analogue is used

Native amylin is unstable and prone to aggregation, which makes it impractical in controlled experiments. Cagrilintide was engineered as a more soluble, longer-lasting analogue, giving researchers a stable tool to probe amylin-receptor biology in study models.

A complementary research pathway

Because amylin and GLP-1 act through different receptors, cagrilintide is frequently studied in combination with GLP-1 analogues such as semaglutide. In the published research literature, engaging both pathways together has drawn interest for its combined effect on metabolic markers in study models. Our articles on GLP-1 analogues and incretin receptors set out the neighbouring pathways.

Form and reconstitution

Cagrilintide is supplied as a lyophilised (freeze-dried) powder for stability and reconstituted with bacteriostatic water before use. Our reconstitution and storage guide covers the method, and every Vela order includes a free 3 mL vial of bacteriostatic water.

Documented quality

Every Vela batch of cagrilintide ships with a certificate of analysis issued within six months of sale, documenting identity and purity for reproducible work.